Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Progenics Pharmaceuticals
New York, New York, United Stateslantheus.com ↗
- Ownership
- Public · LNTH
- Employees
- ~34
- Development stage
- Other
01
Overview
Progenics developed multiple oncology-focused therapeutics and diagnostics. Its radiotherapeutic AZEDRA was approved for rare neuroendocrine tumors. RELISTOR (methylnaltrexone bromide) was commercialized for opioid-induced constipation. The company advanced PSMA-targeted imaging agents and therapeutics into late-stage development or commercialization before its acquisition by Lantheus Holdings.
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- RadiopharmaceuticalMonoclonal antibodyAntibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Partnerships
Salix/Bausch Health for RELISTOR licensingCytogen Corporation/JV on PSMA assets historicallyWyeth/Pfizer on methylnaltrexone development historically
Beyond the preview
Go deeper on Progenics Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Progenics Pharmaceuticals.